Recent evidence also suggests that the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in T2DM patients may confer a protective effect against RVO compared to dipeptidyl peptidase-4 (DPP-4) inhibitors [32]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.